BeyondSpring Inc.
BYSI · Pharmaceutical Preparations · 41.1M shares · +3%/yr ↑ shares · EDGAR filings ↗
Reference price $1.76 · est. market cap ~$72M — last insider sale, 2025-10-17 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
C60Clinical-stage oncology name kept alive by a borderline-positive Phase 3 OS win but constrained by a CRL and a very short cash runway.
Strengths
- DUBLIN-3 NSCLC Phase 3 met OS primary with significance (HR 0.82, p=0.0399) — a genuine de-risking event
- Plinabulin's bone-pain and immunosuppression secondary advantages offer some differentiation
Risks
- Cash runway only ~2.5 quarters (19.6 pct) and $12.6M cash — acute funding risk
- November 2021 FDA Complete Response Letter on the CIN NDA; CIN Phase 3 was only a boundary-touching noninferiority pass
- No product revenue; positive ROE/ROA percentiles are small-number artifacts of a loss-making firm
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Cash burnNegative free cash flow (-19.8M)
Key metrics
Return on equity
3.1%
Return on assets
-3.9%
Current ratio
1.5×
Free cash flow
-$20M
Tangible book value
-$32M
Cash & investments
$13M
Cash runway
2q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-20 | Huang Lan | Gift | 261K | — |
| 2025-10-17 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 46K | $1.76 |
| 2025-10-16 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 86K | $1.72 |
| 2025-10-15 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 18K | $1.65 |
| 2025-10-14 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 28K | $1.65 |
| 2025-10-13 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 107K | $1.70 |
| 2025-10-10 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 2.4K | $1.77 |
| 2025-10-09 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 4.0K | $1.81 |
| 2025-10-08 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 7.5K | $1.77 |
| 2025-10-07 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 2.1K | $1.79 |
| 2025-10-06 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 18K | $1.78 |
| 2025-10-03 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 600 | $1.76 |
| 2025-10-02 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 600 | $1.73 |
| 2025-10-01 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 2.6K | $1.80 |
| 2025-09-30 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 4.5K | $1.81 |
| 2025-09-29 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 500 | $1.75 |
| 2025-09-26 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 600 | $1.68 |
| 2025-09-25 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 700 | $1.66 |
| 2025-09-24 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 2.3K | $1.68 |
| 2025-09-23 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 4.1K | $1.72 |
| 2025-09-22 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 5.4K | $1.83 |
| 2025-09-19 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 3.7K | $1.79 |
| 2025-09-18 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 5.3K | $1.74 |
| 2025-09-17 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 2.3K | $1.83 |
| 2025-09-16 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 840 | $1.88 |
| 2025-09-15 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 2.6K | $1.84 |
| 2025-09-12 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 700 | $1.85 |
| 2025-09-11 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 3.8K | $1.90 |
| 2025-09-10 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 8.2K | $1.93 |
| 2025-09-09 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 9.1K | $1.97 |
| 2025-09-08 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 7.1K | $1.93 |
| 2025-09-05 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 1.1K | $1.86 |
| 2025-09-04 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 803 | $1.82 |
| 2025-09-03 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 1.3K | $1.81 |
| 2025-09-02 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 2.8K | $1.78 |
| 2025-08-29 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 800 | $1.74 |
| 2025-08-28 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 809 | $1.81 |
| 2025-08-27 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 1.3K | $1.78 |
| 2025-08-26 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 2.0K | $1.79 |
| 2025-08-25 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 300 | $1.77 |
| 2025-08-22 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 2.4K | $1.75 |
| 2025-08-21 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 3.0K | $1.79 |
| 2025-08-20 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 3.5K | $1.74 |
| 2025-08-19 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 3.6K | $1.77 |
| 2025-08-18 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 48K | $2.03 |
| 2025-08-15 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 2.9K | $2.00 |
| 2025-08-14 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 2.0K | $2.00 |
| 2025-08-04 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 2.2K | $2.18 |
| 2025-07-18 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 900 | $2.20 |
| 2025-07-17 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 21K | $2.19 |
| 2025-07-16 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 5.4K | $2.24 |
| 2025-07-15 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 2.2K | $2.28 |
| 2025-07-14 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 801 | $2.29 |
| 2025-07-11 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 246 | $2.29 |
| 2025-07-10 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 768 | $2.28 |
| 2025-07-09 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 252 | $2.27 |
| 2025-07-08 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 9.1K | $2.29 |
| 2025-07-02 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 324 | $2.42 |
| 2025-07-01 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 600 | $2.43 |
| 2025-06-23 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 1.7K | $3.09 |
| 2025-06-20 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 60K | $3.11 |
| 2025-06-20 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 225K | $3.16 |
| 2025-06-18 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 59K | $3.17 |
| 2025-06-17 | Decheng Capital China Life Sciences USD Fund III, L.P. | Sell | 5.0K | $3.23 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07361484 ↗ | Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cance | PHASE3 | Not Yet Recruiting | 2029-06-01 |
| NCT02504489 ↗ | Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC Non-Small Cell Lung Cancer | PHASE3 | Completed | 2021-07-21 |
| NCT03294577 ↗ | Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia Chemotherapy-induced Neutropenia | PHASE3 | Unknown | 2020-09-25 |
| NCT03102606 ↗ | Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 Chemotherapy-induced Neutropenia | PHASE3 | Completed | 2018-12-12 |
| NCT04227990 ↗ | Plinabulin iv Solution in Prevention of TAC Induced Neutropenia Chemotherapy-induced Neutropenia | PHASE2 | Completed | 2018-10-15 |
| NCT04345900 ↗ | Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2 Chemotherapy-induced Neutropenia | PHASE2 | Completed | 2018-03-20 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-04 | Exec/director changeReg FDExhibits | filing ↗ |
| 2026-05-13 | ResultsExhibits | filing ↗ |
| 2026-03-25 | ResultsExhibits | filing ↗ |
| 2025-12-15 | Other | filing ↗ |
| 2025-11-21 | Material agreementExhibits | filing ↗ |
| 2025-11-12 | ResultsExhibits | filing ↗ |
| 2025-09-23 | Material agreementOtherExhibits | filing ↗ |
| 2025-09-16 | Shareholder vote | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-04 | 2026-06-04 | 0001171843-26-003908 ↗ |
| 10-Q | 2026-05-13 | 2026-03-31 | 0001171843-26-003372 ↗ |
| 8-K | 2026-05-13 | 2026-05-13 | 0001171843-26-003344 ↗ |
| 10-K | 2026-03-25 | 2025-12-31 | 0001171843-26-001908 ↗ |
| 8-K | 2026-03-25 | 2026-03-25 | 0001171843-26-001890 ↗ |
| 8-K | 2025-12-15 | 2025-12-15 | 0001171843-25-007943 ↗ |
| 8-K | 2025-11-21 | 2025-11-17 | 0001171843-25-007497 ↗ |
| 10-Q | 2025-11-12 | 2025-09-30 | 0001171843-25-007236 ↗ |
| 8-K | 2025-11-12 | 2025-11-12 | 0001171843-25-007217 ↗ |
| 8-K | 2025-09-23 | 2025-09-22 | 0001171843-25-006027 ↗ |
| 8-K | 2025-09-16 | 2025-09-15 | 0001171843-25-005922 ↗ |
| 8-K | 2025-08-13 | 2025-08-13 | 0001171843-25-005355 ↗ |